Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615 1619
This examiner grants 37% of resolved cases
Tigabu Kassa, working in Tech Center 1600 and Art Unit 1615, has resolved 722 cases. The examiner maintains an allowance rate of 36.6%. For successful applications, the median days to allowance is 1562. This duration provides a benchmark for the prosecution timeline for those seeking an allowance.
Interviews appear to be an effective tool, as evidenced by an interview lift of 27.8%. This lift suggests that direct engagement with the examiner may help increase the 36.6% base allowance rate. Practitioners should factor this 27.8% lift into their strategy for the 722 resolved cases. The 1562-day median pendency is a key consideration for applicants. Direct communication may be a productive way to navigate the examination process in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17727123 | EFFERVESCENT ORAL COMPOSITION | Non-Final OA | NICOVENTURES TRADING LIMITED |
| 18315330 | BIOMIMETIC ARTIFICIAL CELLS: ANISOTROPIC SUPPORTED LIPID BILAYERS ON BIODEGRADABLE MICRO AND NANOPARTICLES FOR SPATIALLY DYNAMIC SURFACE BIOMOLECULE PRESENTATION | Final Rejection | The Johns Hopkins University |
| 18187526 | CHEMICAL COMPOSITION | Non-Final OA | The Johns Hopkins University |
| 16851177 | BIOCOMPATIBLE ORGANOGEL MATRICES FOR INTRAOPERATIVE PREPARATION OF A DRUG DELIVERY DEPOT | Final Rejection | DePuy Synthes Products, Inc. |
| 18438184 | BOTTLEBRUSH POLYMERS AND METHODS THEREOF | Non-Final OA | Regents of the University of Minnesota |
| 16858439 | Coated Drug Compositions and Methods of Preparing the Same | Final Rejection | Applied Materials, Inc. |
| 18804677 | PHARMACEUTICAL FORMULATIONS OF BICTEGRAVIR AND LENACAPAVIR | Non-Final OA | Gilead Sciences, Inc. |
| 18538022 | BIODEGRADABLE COMPACTED FORMULATIONS AND METHODS OF USE AND MANUFACTURE THEREOF | Final Rejection | Purdue Research Foundation |
| 18872480 | COMPOSITION FOR CARING FOR AND/OR MAKING UP KERATIN MATERIALS | Non-Final OA | L'OREAL |
| 18867064 | CONCENTRATED CLEANSING COMPOSITIONS | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 17530559 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | Final Rejection | Boehringer Ingelheim International GmbH |
| 17293621 | SURFACTANT-STABILIZED FLUID INTERFACE AND DISPERSION COMPRISING ONE OR MORE DROPLETS HAVING A SURFACTANT STABILIZED FLUID INTERFACE | Final Rejection | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. |
| 18686305 | IRON COMPOSITIONS AND METHODS OF MAKING AND USING THEM | Non-Final OA | American Regent, Inc. |
| 17915826 | ORAL COMPLEX TABLET COMPRISING SITAGLIPTIN, DAPAGLIFLOZIN, AND METFORMIN | Final Rejection | HANMI PHARM. CO., LTD. |
| 18256752 | SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS | Final Rejection | QUEEN MARY UNIVERSITY OF LONDON |
| 18716692 | COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF | Non-Final OA | The Children's Medical Center Corporation |
| 17946610 | POLYELECTROLYTE-LAYER FORMING BLOCK COPOLYMERS AND COMPOSITIONS AND USES THEREOF | Final Rejection | Rhodia Operations |
| 18691949 | ANTI-AGING AGENT, COSMETIC PRODUCT, WET TOWEL, AND HYGIENE PRODUCT | Non-Final OA | VB JAPAN TECHNOLOGY CO., LTD. |
| 18281411 | NOVEL ANTICANCER THERAPY | Non-Final OA | TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy